Rocked by allegations, Novena Global Healthcare board takes over running of firm from Loh cousins
Sinopharm Capital among investors guarding their interests over the company's accounts
Add BT as a preferred source
Anita Gabriel
Singapore
A GROUP of chafed investors in Novena Global Healthcare Group (NGHG) is moving to guard its interests on concerns about the company's accounts. Among these investors: Sinopharm Capital, the private equity arm of Chinese pharmaceutical giant Sinopharm.
On Friday, NGHG's board shot out a statement that it was "deeply concerned" by recent developments, and has set up a special committee to investigate allegations that the audit signatures on the firm's accounts were forged and to "restructure and scrutinise" its affairs.
TRENDING NOW
Orchard plot, Jurong East EC, Raffles Town Club site among 10 new housing parcels in H2 GLS plan
Geopolitical risks must be considered before investing in tech: Temasek chairman Teo Chee Hean
Don’t just pump money – Temasek’s portfolio firms, markets must create inherent value: Teo Chee Hean
Indonesia’s commodity export shake-up sparks industry alarm, investor jitters
